The former includes biologicals like rituximab and frequently-used immunosuppressants such as calcineurin inhibitors (cyclosporine and tacrolimus), cyclophosphamide and glucocorticoids.[12,13] The main therapeutic choices for AIH are glucocorticoids and azathioprine.[14,15] UDCA, a farnesoid X receptor activator, is dramatically used in all patients diagnosed with PBC as first-line therapy.[4] Furthermore, the medication plan for MN with other overlapping AILDs needs further optimization. Here, NR1H4 is linked to primary biliary cholangitis.